← All Sponsors
SPONSOR

CSL Behring

Total Trials
1
Recruiting
1
Phases
Phase 3
Conditions studied: Hemophilia B
NCT06003387 Phase 3
Recruiting

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

Hemophilia B
United States, Australia, Canada View Trial →